The project aims to study the impact of SGLT2i therapy on clinical and biochemical aspects. in elderly. The project will combine different types of data, such as clinical and biological information, and will use advanced Bayesian statistical methods to understand the relationship between risk factors and patient outcomes following treatment with SGLT2 inhibitors.
Participant is willing and able to give informed consent for participation in the study;
Patients must be enrolled also in MED-Cli e MED-Mol studies by signing both the MED-Cli e MED-Mol informed consents.
The medical product is the standard of care for the patient and has been prescribed according to clinical practice and independent of the present study;
Age ≥65 years;
Current or previous use of SGLT2i;
Inability to sign the informed consent.
Chiara Lanzani
Lead sponsor
Ospedale San Raffaele
Sponsor institution